246 related articles for article (PubMed ID: 36238300)
21. Non‑small cell lung cancer carrying PBRM1 mutation suggests an immunologically cold phenotype leading to immunotherapy failure even with high TMB.
Miao XY; Wu H; Ye BC; Yi QW; Lin FN; Wang YL; Ren CL; Jiang YF; Li A
Sci Rep; 2022 Dec; 12(1):20734. PubMed ID: 36456601
[TBL] [Abstract][Full Text] [Related]
22.
Zhang N; Shen J; Gou L; Cao M; Ding W; Luo P; Zhang J
Bioengineered; 2022 May; 13(5):11577-11592. PubMed ID: 35531878
[TBL] [Abstract][Full Text] [Related]
23. The Promises and Challenges of Tumor Mutation Burden as an Immunotherapy Biomarker: A Perspective from the International Association for the Study of Lung Cancer Pathology Committee.
Sholl LM; Hirsch FR; Hwang D; Botling J; Lopez-Rios F; Bubendorf L; Mino-Kenudson M; Roden AC; Beasley MB; Borczuk A; Brambilla E; Chen G; Chou TY; Chung JH; Cooper WA; Dacic S; Lantuejoul S; Jain D; Lin D; Minami Y; Moreira A; Nicholson AG; Noguchi M; Papotti M; Pelosi G; Poleri C; Rekhtman N; Tsao MS; Thunnissen E; Travis W; Yatabe Y; Yoshida A; Daigneault JB; Zehir A; Peters S; Wistuba II; Kerr KM; Longshore JW
J Thorac Oncol; 2020 Sep; 15(9):1409-1424. PubMed ID: 32522712
[TBL] [Abstract][Full Text] [Related]
24. Integrated analysis of single-cell and bulk RNA sequencing data reveals a pan-cancer stemness signature predicting immunotherapy response.
Zhang Z; Wang ZX; Chen YX; Wu HX; Yin L; Zhao Q; Luo HY; Zeng ZL; Qiu MZ; Xu RH
Genome Med; 2022 Apr; 14(1):45. PubMed ID: 35488273
[TBL] [Abstract][Full Text] [Related]
25. A mutation-based gene set predicts survival benefit after immunotherapy across multiple cancers and reveals the immune response landscape.
Long J; Wang D; Wang A; Chen P; Lin Y; Bian J; Yang X; Zheng M; Zhang H; Zheng Y; Sang X; Zhao H
Genome Med; 2022 Feb; 14(1):20. PubMed ID: 35197093
[TBL] [Abstract][Full Text] [Related]
26. Biological and technical factors in the assessment of blood-based tumor mutational burden (bTMB) in patients with NSCLC.
Schuurbiers M; Huang Z; Saelee S; Javey M; de Visser L; van den Broek D; Heuvel MVD; Lovejoy AF; Monkhorst K; Klass D
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35217576
[TBL] [Abstract][Full Text] [Related]
27. Clinical and technical insights of tumour mutational burden in non-small cell lung cancer.
Meri-Abad M; Moreno-Manuel A; García SG; Calabuig-Fariñas S; Pérez RS; Herrero CC; Jantus-Lewintre E
Crit Rev Oncol Hematol; 2023 Feb; 182():103891. PubMed ID: 36565893
[TBL] [Abstract][Full Text] [Related]
28. [Effect of FBXW7 gene mutation on the prognosis of immunotherapy in patients with non-small cell lung cancer].
Liu XY; Cui YN; Li J; Zhang Z; Guo RH
Zhonghua Yi Xue Za Zhi; 2022 Apr; 102(13):914-921. PubMed ID: 35385962
[No Abstract] [Full Text] [Related]
29. Paired analysis of tumor mutation burden calculated by targeted deep sequencing panel and whole exome sequencing in non-small cell lung cancer.
Park S; Lee C; Ku BM; Kim M; Park WY; Kim NKD; Ahn MJ
BMB Rep; 2021 Jul; 54(7):386-391. PubMed ID: 34154699
[TBL] [Abstract][Full Text] [Related]
30. Prediction performance of twelve tumor mutation burden panels in melanoma and non-small cell lung cancer.
Xu D; Li J; Wang D; Zhou L; Jin J; Wang Y
Crit Rev Oncol Hematol; 2022 Jan; 169():103573. PubMed ID: 34933103
[TBL] [Abstract][Full Text] [Related]
31. Combination of TMB and CNA Stratifies Prognostic and Predictive Responses to Immunotherapy Across Metastatic Cancer.
Liu L; Bai X; Wang J; Tang XR; Wu DH; Du SS; Du XJ; Zhang YW; Zhu HB; Fang Y; Guo ZQ; Zeng Q; Guo XJ; Liu Z; Dong ZY
Clin Cancer Res; 2019 Dec; 25(24):7413-7423. PubMed ID: 31515453
[TBL] [Abstract][Full Text] [Related]
32. Tumor mutation burden (TMB)-associated signature constructed to predict survival of lung squamous cell carcinoma patients.
Yan D; Chen Y
Sci Rep; 2021 Apr; 11(1):9020. PubMed ID: 33907270
[TBL] [Abstract][Full Text] [Related]
33. Development and Validation of a Machine Learning Model to Explore Tyrosine Kinase Inhibitor Response in Patients With Stage IV EGFR Variant-Positive Non-Small Cell Lung Cancer.
Song J; Wang L; Ng NN; Zhao M; Shi J; Wu N; Li W; Liu Z; Yeom KW; Tian J
JAMA Netw Open; 2020 Dec; 3(12):e2030442. PubMed ID: 33331920
[TBL] [Abstract][Full Text] [Related]
34. Tumor mutation score is more powerful than tumor mutation burden in predicting response to immunotherapy in non-small cell lung cancer.
Li Y; Chen Z; Tao W; Sun N; He J
Cancer Immunol Immunother; 2021 Aug; 70(8):2367-2378. PubMed ID: 33533944
[TBL] [Abstract][Full Text] [Related]
35. Development and validation of an interpretable radiomic signature for preoperative estimation of tumor mutational burden in lung adenocarcinoma.
Zhang Y; Yang Y; Ma Y; Liu Y; Ye Z
Front Genet; 2024; 15():1367434. PubMed ID: 38660677
[TBL] [Abstract][Full Text] [Related]
36. HLA-corrected tumor mutation burden and homologous recombination deficiency for the prediction of response to PD-(L)1 blockade in advanced non-small-cell lung cancer patients.
Shim JH; Kim HS; Cha H; Kim S; Kim TM; Anagnostou V; Choi YL; Jung HA; Sun JM; Ahn JS; Ahn MJ; Park K; Park WY; Lee SH
Ann Oncol; 2020 Jul; 31(7):902-911. PubMed ID: 32320754
[TBL] [Abstract][Full Text] [Related]
37. Clinical Implications of Circulating Tumor DNA Tumor Mutational Burden (ctDNA TMB) in Non-Small Cell Lung Cancer.
Chae YK; Davis AA; Agte S; Pan A; Simon NI; Iams WT; Cruz MR; Tamragouri K; Rhee K; Mohindra N; Villaflor V; Park W; Lopes G; Giles FJ
Oncologist; 2019 Jun; 24(6):820-828. PubMed ID: 30867242
[TBL] [Abstract][Full Text] [Related]
38. HLA-I diversity and tumor mutational burden by comprehensive next-generation sequencing as predictive biomarkers for the treatment of non-small cell lung cancer with PD-(L)1 inhibitors.
Cuppens K; Baas P; Geerdens E; Cruys B; Froyen G; Decoster L; Thomeer M; Maes B
Lung Cancer; 2022 Aug; 170():1-10. PubMed ID: 35689896
[TBL] [Abstract][Full Text] [Related]
39. Identification of a small mutation panel of coding sequences to predict the efficacy of immunotherapy for lung adenocarcinoma.
Li Y; Jiang W; Li T; Li M; Li X; Zhang Z; Zhang S; Liu Y; Zhao W; Gu Y; Qi L; Ao L; Guo Z
J Transl Med; 2020 Jan; 18(1):25. PubMed ID: 31937321
[TBL] [Abstract][Full Text] [Related]
40. Burden of tumor mutations, neoepitopes, and other variants are weak predictors of cancer immunotherapy response and overall survival.
Wood MA; Weeder BR; David JK; Nellore A; Thompson RF
Genome Med; 2020 Mar; 12(1):33. PubMed ID: 32228719
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]